Trial Profile

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 19 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nivolumab/relatlimab (Primary) ; Carboplatin; Cisplatin; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Therapeutic Use
Acronyms RELATIVITY1093
Sponsors Bristol-Myers Squibb

15 Jan 2025 Planned number of patients changed from 800 to 1000.
23 Sep 2024 Status changed from not yet recruiting to recruiting.
09 Sep 2024 According to a Bristol-Myers Squibb media release, company is initiating Phase 3 RELATIVITY-1093 trial supported by findings from the RELATIVITY-104 trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com